Skip to main content
SpringerLink
Log in

Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

  • Editorial
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–50.

    PubMed  CAS  Google Scholar 

  2. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164–7.

    PubMed  CAS  Google Scholar 

  3. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996;17:890–4.

    Article  PubMed  CAS  Google Scholar 

  4. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441–4.

    PubMed  CAS  Google Scholar 

  5. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345–8.

    Article  PubMed  CAS  Google Scholar 

  6. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual-time-point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871–5.

    PubMed  Google Scholar 

  7. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 2005;46:1819–24.

    PubMed  Google Scholar 

  8. Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006;47:1440–6.

    PubMed  Google Scholar 

  9. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226–30.

    Article  PubMed  CAS  Google Scholar 

  10. Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006;47:633–8.

    PubMed  Google Scholar 

  11. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed 18F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775–83.

    PubMed  Google Scholar 

  12. Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 2004;45:1653–9.

    PubMed  Google Scholar 

  13. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154–61.

    PubMed  CAS  Google Scholar 

  14. Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996;23:533–41.

    Article  PubMed  CAS  Google Scholar 

  15. Suzuki S, Toyota T, Suzuki H, Goto Y. Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase. Arch Biochem Biophys 1984;235:418–26.

    Article  PubMed  CAS  Google Scholar 

  16. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308–12.

    PubMed  CAS  Google Scholar 

  17. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22–30.

    Article  PubMed  CAS  Google Scholar 

  18. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412–7.

    PubMed  CAS  Google Scholar 

  19. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer’s disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993;34:1681–7.

    PubMed  CAS  Google Scholar 

  20. Kohn MI, Tanna NK, Herman GT, Resnick SM, Mozley PD, Gur RE, et al. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology 1991;178:115–22.

    PubMed  CAS  Google Scholar 

  21. Baete K, Nuyts J, Van Laere K, Van Paesschen W, Ceyssens S, De Ceuninck L, et al. Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. NeuroImage 2004;23:305–17.

    Article  PubMed  Google Scholar 

  22. Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L, et al. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med 2004;45:192–201.

    PubMed  Google Scholar 

  23. Aston JAD, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN. Positron emission tomography partial volume correction: estimation and algorithms. J Cereb Blood Flow Metab 2002;22:1019–34.

    Article  PubMed  Google Scholar 

  24. Weber W, Young C, Abdel-Dayem HM, Sfakianakis G, Weir GJ, Swaney CM, et al. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999;40:574–8.

    PubMed  CAS  Google Scholar 

  25. Lubberink M, Tolmachev V, Widstrom C, Bruskin A, Lundqvist H, Westlin JE. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002;43:1391–7.

    PubMed  CAS  Google Scholar 

  26. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639–47.

    Article  PubMed  Google Scholar 

  27. Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997;38:1186–91.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the International Union against Cancer (UICC), Geneva, Switzerland, under the ACSBI fellowship.

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, 19104, USA

    Sandip Basu & Abass Alavi

Authors
  1. Sandip Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abass Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abass Alavi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basu, S., Alavi, A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?. Eur J Nucl Med Mol Imaging 34, 1527–1529 (2007). https://doi.org/10.1007/s00259-007-0467-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0467-5

Search

Navigation